NXTS vs ARGX vs GRFS Stock Comparison

Nexentis Technologies, Argenx Se and Grifols Prices as of Oct 26, 2026 Peers: Industry group
ARGX Argenx Se
$869.33 -9.4% 1M +6.4% 1Y
Market cap
$53.48B
P/E
28.5x
Revenue (TTM)
$5.82B
Div. yield
–
Biotechnology Healthcare
4 wins
GRFS Grifols SA
$7.92 +7.8% 1M -16.3% 1Y
Market cap
$5.41B
P/E
11.9x
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare
3 wins

Head to Head

7 decided of 12

Argenx Se leads on 4 of the 12 questions below (Argenx Se 4, Grifols 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNXTSARGXGRFSLeader
Larger companyMarket capitalisation $450.51K $53.48B $5.41B ARGX
Cheaper on earningsLower P/E, profitable companies only 0.0x 28.5x 11.9x GRFS
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 28.4x 8.4x GRFS
Faster revenue growthRevenue growth, trailing twelve months — +61.5% — –
More profitableNet margin, trailing twelve months — 32.3% — –
Better return on capitalReturn on invested capital — — — –
Less leveragedLower net debt / EBITDA 1.6x — — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -97.9% +6.4% -16.3% ARGX
Better 5-year returnAnnualised price return, 5 years -86.1%/yr +25.5%/yr -9.9%/yr ARGX
Less volatileAnnualised volatility, 1 year 169.1% 37.0% 32.4% GRFS
Higher overall scoreMean of the five percentile scores vs peers 32/100 92/100 57/100 ARGX

Percentile Scorecard

NXTSARGXGRFS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNXTSARGXGRFS
Valuation – 83 #108 of 626 99 #6 of 626
Growth 13 #526 of 604 95 #34 of 604 –
Profitability 40 #333 of 555 98 #11 of 555 –
Financial Health 44 #372 of 658 – 14 #566 of 658
Shareholder Returns – – 56 #161 of 368
Overall 32 92 57
  • NXTS ranked among 673 companies in Pharmaceuticals and Biotechnology
  • ARGX ranked among 673 companies in Pharmaceuticals and Biotechnology
  • GRFS ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNXTSARGXGRFSSPY
1 month -61.9%-9.4%+7.8% -0.8%
3 months -66.5%-2.2%+2.2% +3.5%
6 months -88.4%+10.9%-2.6% +7.0%
Year to date -95.2%+3.4%-15.3% +12.2%
1 year -97.9%+6.4%-16.3% +13.0%
3 years -99.9%+89.0%+1.0% +86.3%
3 years, per year -89.6%+23.7%+0.3% +23.1%
5 years -100.0%+210.9%-40.5% +68.6%
5 years, per year -86.1%+25.5%-9.9% +11.0%
10 years -100.0%—-46.6% +258.0%
10 years, per year -66.6%—-6.1% +13.6%

Risk

MeasureNXTSARGXGRFSSPY
Volatility, 1Y 169.1%37.0%32.4% 12.7%
Downside volatility, 1Y 153.3%34.6%34.1% 12.7%
Beta vs S&P 500, 1Y 2.310.390.95 1.00
Return / volatility, 1Y -0.580.17-0.50 1.02
Max drawdown, 5Y -100.0%-38.2%-58.9% -25.4%
From 52-week high -97.8%-17.9%-18.5% -1.8%
52-week high $26.04$1,058.90$9.72 $779.14
52-week low $0.53$663.93$7.02 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNXTSARGXGRFS
P/E now vs peer median 0.0xmedian 17.1x 28.4xmedian 17.1x 11.9xmedian 17.1x
P/S now vs peer median —median 8.8x 9.2xmedian 8.8x 0.6xmedian 8.8x
EV/EBITDA now vs peer median 1.5xmedian 17.1x —median 17.1x —median 17.1x
P/FCF now vs peer median —median 18.0x —median 18.0x 7.6xmedian 18.0x
P/B now vs peer median 0.2xmedian 2.1x —median 2.1x 0.6xmedian 2.1x
PEG now vs peer median 0.00median 0.31 0.27median 0.31 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNXTSARGXGRFS
Revenue – $5.82B –
Gross profit – $5.24B –
Operating income -$5.28M $1.74B –
Net income -$14.06M $1.88B –
R&D $532.00K $1.80B –
EPS (diluted) $-17.10 $28.43 –
Cash & equivalents $7.62M – $969.15M
Total debt $3.22M – $44.00B
Shares (diluted) 816.14K 66.03M 681.57M
Enterprise value -$22.19M $53.48B $1.76B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNXTSARGXGRFS
P/E 0.0x 28.4x 11.9x
P/FCF – – 7.6x
P/Operating cash flow – – –
P/S – 9.2x 0.6x
P/B 0.2x – 0.6x
P/Tangible book -0.2x – 0.9x
EV/EBITDA 1.5x – –
EV/EBIT 1.5x 30.9x –
EV/Revenue – 9.2x –
EV/FCF – – –
EV/Operating cash flow – – –
PEG (3Y EPS CAGR) 0.00 0.27 –

Growth

14 metrics
MetricNXTSARGXGRFS
Revenue growth (1Y) – 61.5% –
Revenue CAGR (3Y) – 80.5% –
Gross profit growth (1Y) – 62.2% –
Gross profit CAGR (3Y) – 80.0% –
Operating income growth (1Y) -7.7% 120.6% –
Operating income CAGR (3Y) 3.0% 85.1% –
Net income growth (1Y) -48.2% 22.5% –
Net income CAGR (3Y) -35.8% 115.5% –
EPS growth (1Y) -567.8% 20.9% –
EPS CAGR (3Y) -45.2% 104.8% –
Operating cash flow growth (1Y) – – –
Operating cash flow CAGR (3Y) – – –
Free cash flow growth (1Y) – – –
Free cash flow CAGR (3Y) – – –

Profitability

14 metrics
MetricNXTSARGXGRFS
Gross margin – 90.0% –
EBITDA margin – – –
Operating margin – 29.9% –
Pretax margin – 32.6% –
Net margin – 32.3% –
FCF margin – – –
Operating cash flow margin – – –
Return on equity -157.0% – –
Return on assets -71.9% – –
Return on invested capital – – –
Return on capital employed -31.5% – –
Asset turnover – – –
Cash conversion (OCF / net income) – – –
Stock comp / revenue – – –

Financial Health

11 metrics
MetricNXTSARGXGRFS
Debt / assets 2.3% – 48.9%
Debt / equity 0.2x – 1.3x
Net debt / EBITDA 1.6x – –
Debt / FCF – – –
Liabilities / assets 89.8% – 61.4%
Equity / assets 10.2% – 38.6%
Interest coverage – 10,120x –
Current ratio 3.7x – 2.5x
Quick ratio 3.2x – 0.8x
Cash ratio 3.2x – 0.4x
Altman Z-score – – –

Shareholder Returns

7 metrics
MetricNXTSARGXGRFS
Dividend yield – – 1.4%
Net buyback yield – – –
Shareholder yield – – 1.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNXTSARGXGRFS
Forward P/E – 28.4xFY2026 8.4xFY2026
EPS, next fiscal year – $30.63FY2026 $0.94FY2026
EPS growth, next FY – +56.5%FY2026 +10.6%FY2026
EPS growth, the year after – +26.9% +26.6%
Revenue, next fiscal year – $6.08BFY2026 $8.88BFY2026
Revenue growth, next FY – +43.1%FY2026 +0.0%FY2026
Revenue growth, the year after – +22.9% +10.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNXTSARGXGRFS
Held by institutions – 46.1% 21.0%
Institutions holding – 504 166
Change in shares held, QoQ – -2.0% -0.5%
Institutions buying – 264 73
Institutions selling – 160 65
Buyers to sellers – 1.65 1.12

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NXTSARGXGRFS
NXTS 1.00 0.12 0.03
ARGX 0.12 1.00 0.15
GRFS 0.03 0.15 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NXTS, ARGX and GRFS?

Argenx Se (ARGX) is the largest by market capitalisation: Nexentis Technologies (NXTS) $450.51K, Argenx Se (ARGX) $53.48B, Grifols (GRFS) $5.41B.

Which stock is cheaper, NXTS, ARGX and GRFS?

Grifols (GRFS) trades on the lowest price-to-earnings ratio (Nexentis Technologies (NXTS) 0.0x, Argenx Se (ARGX) 28.5x, Grifols (GRFS) 11.9x). On next year's consensus earnings, Grifols (GRFS) is cheapest (Argenx Se (ARGX) 28.4x, Grifols (GRFS) 8.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which stock has performed better?

Over the past year Argenx Se (ARGX) returned the most: Nexentis Technologies (NXTS) -97.9%, Argenx Se (ARGX) +6.4%, Grifols (GRFS) -16.3%. Over five years, Argenx Se (ARGX) compounded fastest (Nexentis Technologies (NXTS) -86.1%/yr, Argenx Se (ARGX) +25.5%/yr, Grifols (GRFS) -9.9%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Grifols (GRFS) has been the steadiest (Nexentis Technologies (NXTS) 169.1%, Argenx Se (ARGX) 37.0%, Grifols (GRFS) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NXTS, ARGX and GRFS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Argenx Se (ARGX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.